Generation Bio Co. (NASDAQ:GBIO) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Generation Bio Co. (NASDAQ:GBIO) have been given a consensus recommendation of “Hold” by the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $8.8750.

Several research firms have commented on GBIO. Wall Street Zen raised shares of Generation Bio to a “sell” rating in a research note on Saturday, February 14th. Wedbush set a $5.50 target price on shares of Generation Bio and gave the stock an “outperform” rating in a research report on Tuesday, December 16th. Needham & Company LLC reissued a “buy” rating and issued a $15.00 price target on shares of Generation Bio in a research note on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Generation Bio in a research note on Thursday, January 22nd. Finally, Jefferies Financial Group downgraded Generation Bio from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $11.00 to $5.00 in a report on Tuesday, December 16th.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC bought a new stake in Generation Bio during the 1st quarter valued at $36,000. Acadian Asset Management LLC raised its stake in shares of Generation Bio by 54.3% during the first quarter. Acadian Asset Management LLC now owns 1,159,135 shares of the company’s stock valued at $468,000 after acquiring an additional 407,843 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in shares of Generation Bio during the second quarter worth about $47,000. Marshall Wace LLP purchased a new stake in shares of Generation Bio during the second quarter worth about $37,000. Finally, Militia Capital Partners LP purchased a new position in Generation Bio during the 2nd quarter valued at about $174,000. 95.22% of the stock is owned by hedge funds and other institutional investors.

Generation Bio Price Performance

NASDAQ:GBIO opened at $5.34 on Friday. The business has a 50 day moving average of $5.51 and a 200 day moving average of $5.70. The company has a market capitalization of $35.99 million, a price-to-earnings ratio of -0.57 and a beta of 2.05. Generation Bio has a 1-year low of $3.00 and a 1-year high of $8.20.

About Generation Bio

Generation Bio, Inc (NASDAQ: GBIO) is a clinical-stage genetic medicine company dedicated to developing ultra-long-term non-viral gene therapies for serious, chronic diseases. Headquartered in Cambridge, Massachusetts, Generation Bio focuses on harnessing its proprietary Gene Delivery System to deliver plasmid DNA payloads via lipid nanoparticles, enabling durable expression of therapeutic proteins in target tissues without the use of viral vectors.

The company’s lead approach is centered on a modular platform designed to address monogenic disorders and other chronic conditions that require continuous protein replacement or modulation.